iTheranostics, Novartis ink FAP-targeted drug development agreement

By The Science Advisory Board staff writers

April 12, 2021 -- Sofie subsidiary iTheranostics has inked an agreement with Novartis to collaborate on the development of therapeutic fibroblast activation protein (FAP)-targeted agents.

iTheranostics' library of these drugs has been licensed from the University of Heidelberg in Germany. Under the terms of the deal, Novartis will develop therapeutic uses of this family of compounds, while iTheranostics will be responsible for commercializing the developed imaging agents.

Sofie may facilitate clinical supply and will be responsible for the commercialization of FAP-targeted positron emission tomography (PET) imaging tracers around the world, it said.


Copyright © 2021 scienceboard.net
 


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.